Saturday, October 14, 2017

Newly approved breast cancer drug may work for lung cancer


This image shows autophagic vesicles containing
mutant K-Ras formed in the membrane of human
pancreatic cancer cells after exposure to neratinib –
Image courtesy VCU.
CANCER DIGEST – Oct. 14, 2017 – Researchers have found that a recently approved breast cancer drug may block the action of a trio of cancer-causing genes, known as Ras, which are implicated in a number of other cancers, including non-small cell lung cancer.

The drug neratinib was designed to inhibit enzymes produced by two other genes, EGFR and HER2, which make enzymes that regulate cancer cell growth and resistance to chemotherapy.

Wednesday, October 4, 2017

Do expensive new cancer drugs really improve survival?


CANCER DIGEST – Oct. 4, 2017 – That’s the question a group of British researchers at King’s College in London asked for a study published today in the British Medical Journal (BMJ).

The study looked at the clinical data for cancer drugs approved by the European Medicines Agency, the European version of the US FDA, between 2009 and 2013. They found that of the 68 drugs approved during that period, 39 (57%) were approved on the basis of surrogate endpoints. This is essentially an endpoint that is substituted for an actual outcome. This is done to speed approvals of certain drugs.